

# Michael Platten

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4668070/michael-platten-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

246 papers	18,207 citations	67 h-index	132 g-index
279 ext. papers	23,418 ext. citations	8.5 avg, IF	6.44 L-index

#	Paper	IF	Citations
246	The current landscape of immunotherapy for pediatric brain tumors.. <i>Nature Cancer</i> , <b>2022</b> , 3, 11-24	15.4	1
245	Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM.. <i>Nature</i> , <b>2022</b> ,	50.4	51
244	Consistency of the "central vein sign" in chronic multiple sclerosis lesions.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 58, 103530	4	0
243	Long-term dynamics of multiple sclerosis iron rim lesions.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 57, 103340	4	3
242	Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation: A survey among German stroke units.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0264122	3.7	
241	MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.. <i>Journal of Neurology</i> , <b>2022</b> , 1	5.5	2
240	The remains of the day: neuropsychological findings in postacute transient global amnesia.. <i>Journal of Neurology</i> , <b>2022</b> , 1	5.5	0
239	Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers. <i>Blood</i> , <b>2021</b> , 138, 731-731	2.2	1
238	IMMU-04. UNVEILING THE TUMOR-METABOLOME-IMMUNITY AXIS OF GLIOMA. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi92-vi92	1	
237	PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi123-vi124	1	
236	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , <b>2021</b> , 3, e784-e794	14.4	6
235	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3839-3852	2.2	8
234	Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 356-375	1	28
233	Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2021</b> , 41, 1536-1546	7.3	4
232	A vaccine targeting mutant IDH1 in newly diagnosed glioma. <i>Nature</i> , <b>2021</b> , 592, 463-468	50.4	68
231	MRI topography of lesions related to internuclear ophthalmoplegia in patients with multiple sclerosis or ischemic stroke. <i>Journal of Neuroimaging</i> , <b>2021</b> , 31, 471-474	2.8	0
230	Diffusely appearing white matter in multiple sclerosis: Insights from sodium (Na) MRI. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 49, 102752	4	1

229	Impaired semantic memory during acute transient global amnesia. <i>Journal of Neuropsychology</i> , <b>2021</b> ,	2.6	1
228	Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas.. <i>Nature Cancer</i> , <b>2021</b> , 2, 723-740	15.4	17
227	Characterization of chronic active multiple sclerosis lesions with sodium ( Na) magnetic resonance imaging-preliminary observations. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 2392-2395	6	1
226	Quantitative MRI texture analysis in chronic active multiple sclerosis lesions. <i>Magnetic Resonance Imaging</i> , <b>2021</b> , 79, 97-102	3.3	3
225	Chronobiology of transient global amnesia. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	3
224	Sex-related differences in stressful events precipitating transient global amnesia - A retrospective observational study. <i>Journal of the Neurological Sciences</i> , <b>2021</b> , 425, 117464	3.2	2
223	Tryptophan metabolism in brain tumors - IDO and beyond. <i>Current Opinion in Immunology</i> , <b>2021</b> , 70, 57-66	6.8	10
222	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors <b>2021</b> , 9,		11
221	Decreased utilization of mental health emergency service during the COVID-19 pandemic. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2021</b> , 271, 377-379	5.1	53
220	Venous Diameter Changes in Chronic Active Multiple Sclerosis Lesions. <i>Journal of Neuroimaging</i> , <b>2021</b> , 31, 394-400	2.8	4
219	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 170-186	19.4	204
218	Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma. <i>Onc Immunology</i> , <b>2021</b> , 10, 1920739	7.2	2
217	A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
216	Hypoxia Routes Tryptophan Homeostasis Towards Increased Tryptamine Production. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 590532	8.4	4
215	Central retinal artery occlusion as a neuro-ophthalmological emergency: the need to raise public awareness. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 2111-2114	6	4
214	Vergleichbare Effekte auf das Gesamtberleben. <i>InFo Neurologie &amp; Psychiatrie</i> , <b>2021</b> , 23, 18-18	0	0
213	Intrathecal activation of CD8 memory T cells in IgG4-related disease of the brain parenchyma. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e13953	12	1
212	Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, vdab147	0.9	0

211	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	4
210	Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis. <i>European Radiology</i> , <b>2021</b> , 1	8	5
209	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , <b>2021</b> , 12, 498	17.4	74
208	Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. <i>Theranostics</i> , <b>2021</b> , 11, 9217-9233	12.1	1
207	Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBP $\beta$ . <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 657	8.4	16
206	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1667-1676	1	4
205	Diffusion-weighted MRI in transient global amnesia and its diagnostic implications. <i>Neurology</i> , <b>2020</b> , 95, e206-e212	6.5	25
204	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. <i>BMC Cancer</i> , <b>2020</b> , 20, 523	4.8	11
203	Acute Stroke in Times of the COVID-19 Pandemic: A Multicenter Study. <i>Stroke</i> , <b>2020</b> , 51, 2224-2227	6.7	110
202	-CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 747	5.3	5
201	Comparing Expert and Non-Expert Assessment of Patients Presenting with Neurological Symptoms to the Emergency Department: A Retrospective Observational Study. <i>Neuropsychiatric Disease and Treatment</i> , <b>2020</b> , 16, 447-456	3.1	2
200	Molecular profiling-based decision for targeted therapies in wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, vdz060	0.9	2
199	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1162-1172	1	22
198	Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. <i>Nature Communications</i> , <b>2020</b> , 11, 931	17.4	57
197	Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM). <i>Theranostics</i> , <b>2020</b> , 10, 1873-1883	12.1	15
196	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1073-1113	1	178
195	The therapeutic potential of targeting tryptophan catabolism in cancer. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 30-44	8.7	79
194	Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma. <i>Cancer Medicine</i> , <b>2020</b> , 9, 1263-1275	4.8	5

193	cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. <i>Journal of Neuro-Oncology</i> , <b>2020</b> , 146, 9-23	4.8	7
192	Hepatocyte-intrinsic type I interferon signaling reprograms metabolism and reveals a novel compensatory mechanism of the tryptophan-kynurenine pathway in viral hepatitis. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008973	7.6	2
191	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , <b>2020</b> , 9, 8373-8385	4.8	7
190	Changes in Demographic and Diagnostic Spectra of Patients with Neurological Symptoms Presenting to an Emergency Department During the COVID-19 Pandemic: A Retrospective Cohort Study. <i>Neuropsychiatric Disease and Treatment</i> , <b>2020</b> , 16, 2221-2227	3.1	1
189	Decreased admissions and change in arrival mode in patients with cerebrovascular events during the first surge of the COVID-19 pandemic. <i>Neurological Research and Practice</i> , <b>2020</b> , 2, 47	3.2	0
188	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , <b>2020</b> , 297, 164-175	20.5	7
187	Investigation of the "central vein sign" in infratentorial multiple sclerosis lesions. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 45, 102409	4	3
186	Susceptibility-Weighted 3T MRI of the Swallow Tail Sign in Multiple Sclerosis: A Case Control Study. <i>Journal of Neuroimaging</i> , <b>2020</b> , 30, 766-768	2.8	1
185	Driving mesenchymal transition in glioblastoma. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1-2	1	5
184	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. <i>Acta Neuropathologica Communications</i> , <b>2019</b> , 7, 163	7.3	18
183	Interaction between the heart and the brain in transient global amnesia. <i>Journal of Neurology</i> , <b>2019</b> , 266, 3048-3057	5.5	8
182	Temporal evolution of acute multiple sclerosis lesions on serial sodium (Na) MRI. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 29, 48-54	4	14
181	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , <b>2019</b> , 18, 1255-1268	7.6	26
180	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , <b>2019</b> , 92, e2754-e2763	6.5	6
179	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 837-853	1	37
178	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology</i> , <b>2019</b> , 20, 728-740	21.7	160
177	How to integrate immunotherapy into standard of care in glioblastoma. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 699-700		4
176	Susceptibility-weighted imaging in malignant melanoma brain metastasis. <i>Journal of Magnetic Resonance Imaging</i> , <b>2019</b> , 50, 1251-1259	5.6	5

175	Single-Cell High-Throughput Technologies in Cerebrospinal Fluid Research and Diagnostics. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1302	8.4	5
174	Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology. <i>Nature Communications</i> , <b>2019</b> , 10, 4877	17.4	41
173	Uncompleted emergency department care and discharge against medical advice in patients with neurological complaints: a chart review. <i>BMC Emergency Medicine</i> , <b>2019</b> , 19, 52	2.4	9
172	Characterization of Contrast-Enhancing and Non-contrast-enhancing Multiple Sclerosis Lesions Using Susceptibility-Weighted Imaging. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 1082	4.1	15
171	Abstract 4454: Identification of BAY-218, a potent and selective small-molecule AhR inhibitor, as a new modality to counteract tumor immunosuppression <b>2019</b> ,		8
170	Fulminant Cytotoxic Edema in a Patient with Pneumococcal Meningoencephalitis. <i>Journal of Clinical Neurology (Korea)</i> , <b>2019</b> , 15, 575-577	1.7	1
169	The use of a dedicated neurological triage system improves process times and resource utilization: a prospective observational study from an interdisciplinary emergency department. <i>Neurological Research and Practice</i> , <b>2019</b> , 1, 29	3.2	
168	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. <i>Nature Reviews Drug Discovery</i> , <b>2019</b> , 18, 379-401	64.1	352
167	TCR validation toward gene therapy for cancer. <i>Methods in Enzymology</i> , <b>2019</b> , 629, 419-441	1.7	4
166	High-throughput discovery of cancer-targeting TCRs. <i>Methods in Enzymology</i> , <b>2019</b> , 629, 401-417	1.7	2
165	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , <b>2019</b> , 565, 240-245	50.4	388
164	Acute Corticonuclear Tract Ischemic Stroke with Isolated Central Facial Palsy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2019</b> , 28, 495-498	2.8	1
163	Diffusion-weighted imaging of the dentate nucleus after repeated application of gadolinium-based contrast agents in multiple sclerosis. <i>Magnetic Resonance Imaging</i> , <b>2019</b> , 58, 1-5	3.3	10
162	MRI of Iron Oxide Nanoparticles and Myeloperoxidase Activity Links Inflammation to Brain Edema in Experimental Cerebral Malaria. <i>Radiology</i> , <b>2019</b> , 290, 359-367	20.5	7
161	Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study. <i>Journal of Neuroimaging</i> , <b>2019</b> , 29, 190-192	2.8	4
160	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 95-105	1	55
159	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 253-265	12.9	23
158	Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease. <i>Frontiers in Neuroscience</i> , <b>2018</b> , 12, 1004	5.1	10

157	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 153-166	14.3	162
156	Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 777-787	10.2	79
155	Off-label use of IV t-PA in patients with intracranial neoplasm and cavernoma. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 1756285617753423	6.6	1
154	Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. <i>Molecular Cancer Research</i> , <b>2018</b> , 16, 767-776	6.6	14
153	Spatiotemporal evolution of venous narrowing in acute MS lesions. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2018</b> , 5, e440	9.1	7
152	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 826-837	1	27
151	Immunotherapy of Gliomas <b>2018</b> , 657-664		
150	Fourier Transform Infrared Microscopy Enables Guidance of Automated Mass Spectrometry Imaging to Predefined Tissue Morphologies. <i>Scientific Reports</i> , <b>2018</b> , 8, 313	4.9	26
149	Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 4-5	1	3
148	Vaccine Strategies in Gliomas. <i>Current Treatment Options in Neurology</i> , <b>2018</b> , 20, 11	4.4	7
147	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , <b>2018</b> , 555, 469-474	50.4	992
146	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 273-291	14.3	99
145	Concepts for Immunotherapies in Gliomas. <i>Seminars in Neurology</i> , <b>2018</b> , 38, 62-72	3.2	17
144	Glioblastoma in elderly patients: solid conclusions built on shifting sand?. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 174-183		24
143	Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, 324-326	5.5	6
142	Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 557-566	1	16
141	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 367-379	1	35
140	Understanding and Treating Glioblastoma. <i>Neurologic Clinics</i> , <b>2018</b> , 36, 485-499	4.5	12



139	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , <b>2018</b> , 17, 2132-2145	7.6	16
138	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , <b>2018</b> , 24, 1192-1203	50.5	174
137	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2001-2001	2.2	15
136	IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi133-vi133	1	78
135	Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. <i>Current Opinion in Oncology</i> , <b>2018</b> , 30, 368-374	4.2	10
134	Upregulation of tryptophanyl-tRNA synthetase adapts human cancer cells to nutritional stress caused by tryptophan degradation. <i>Onc Immunology</i> , <b>2018</b> , 7, e1486353	7.2	33
133	Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 1472-1480	4	4
132	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 181-210	14.3	148
131	Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. <i>Onc Immunology</i> , <b>2017</b> , 6, e1274477	7.2	17
130	Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. <i>Scientific Reports</i> , <b>2017</b> , 7, 41271	4.9	32
129	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. <i>Acta Neuropathologica</i> , <b>2017</b> , 133, 629-644	14.3	115
128	Synovial Fibroblasts Selectively Suppress Th1 Cell Responses through IDO1-Mediated Tryptophan Catabolism. <i>Journal of Immunology</i> , <b>2017</b> , 198, 3109-3117	5.3	15
127	Suppression of Th1 differentiation by tryptophan supplementation in vivo. <i>Amino Acids</i> , <b>2017</b> , 49, 1169-1175	11.5	15
126	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , <b>2017</b> , 13, 363-374	15	82
125	Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. <i>Journal of Neurology</i> , <b>2017</b> , 264, 341-349	5.5	15
124	Structural Basis for Aryl Hydrocarbon Receptor-Mediated Gene Activation. <i>Structure</i> , <b>2017</b> , 25, 1025-1033	3.3	50
123	Tweety-Homolog 1 Drives Brain Colonization of Gliomas. <i>Journal of Neuroscience</i> , <b>2017</b> , 37, 6837-6850	6.6	62
122	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , <b>2017</b> , 18, 682-694	21.7	336



121	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , <b>2017</b> , 133, 325-327	14.3	10
120	The promises of immunotherapy in gliomas. <i>Current Opinion in Neurology</i> , <b>2017</b> , 30, 650-658	7.1	10
119	EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough?. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 1425-1426		10
118	HIV-Associated Cerebellar Dysfunction and Improvement with Aminopyridine Therapy: A Case Report. <i>Case Reports in Neurology</i> , <b>2017</b> , 9, 121-126	1	2
117	Immuntherapien bei Gliomen. <i>Onkologe</i> , <b>2017</b> , 23, 831-837	0.1	
116	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1954-1963	59.2	425
115	K27M-mutant histone-3 as a novel target for glioma immunotherapy. <i>OncolImmunology</i> , <b>2017</b> , 6, e13283402	40.2	47
114	Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1479	8.4	77
113	VXM01 phase I study in patients with resectable progression of a glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2061-2061	2.2	2
112	Current status and future directions of anti-angiogenic therapy for gliomas. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 315-28	1	44
111	Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 129, 533-539	4.8	4
110	The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. <i>OncolImmunology</i> , <b>2016</b> , 5, e1240858	7.2	34
109	In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 13227-13232	11.5	69
108	Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 99	8.5	7
107	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 903-10	14.3	151
106	EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2001-2001	2.2	34
105	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2019-2019	2.2	11
104	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS2082-TPS2082	2.2	5

103	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N <sup>2</sup> MD <sup>2</sup> ).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS2084-TPS2084	2.2	4
102	Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155322	3.7	2
101	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. <i>Oncotarget</i> , <b>2016</b> , 7, 82028-82045	3.3	15
100	Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis. <i>ELife</i> , <b>2016</b> , 5, e11712	8.9	28
99	Effect of Glioma N-Myc downstream regulated gene 1 (NDRG1) on the tumor microenvironment.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11587-11587	2.2	
98	Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. <i>Oncotarget</i> , <b>2016</b> , 7, 56713-56725	3.3	18
97	Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. <i>Journal of Neurochemistry</i> , <b>2016</b> , 136, 1142-1154	6	37
96	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. <i>BMJ Open</i> , <b>2016</b> , 6, e010956	3	38
95	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1529-1537	1	80
94	Neurological sequelae of cancer immunotherapies and targeted therapies. <i>Lancet Oncology</i> , <b>2016</b> , 17, e529-e541	21.7	59
93	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4797-4806	12.9	77
92	General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. <i>Journal of Neuroimmunology</i> , <b>2016</b> , 297, 117-26	3.5	15
91	Highlights in Central Nervous System Tumors. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1535-1536	13.4	1
90	Concepts in glioma immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2016</b> , 65, 1269-75	7.4	40
89	Normal mast cell numbers in the tissues of AhR-deficient mice. <i>Experimental Dermatology</i> , <b>2016</b> , 25, 62-34		5
88	Cancer immunotherapy: exploiting neoepitopes. <i>Cell Research</i> , <b>2015</b> , 25, 887-8	24.7	18
87	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. <i>Acta Neuropathologica</i> , <b>2015</b> , 130, 407-17	14.3	194
86	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2057-64	12.9	206

85	Brain tumour cells interconnect to a functional and resistant network. <i>Nature</i> , <b>2015</b> , 528, 93-8	50.4	496
84	Toxicity of teriflunomide in aryl hydrocarbon receptor deficient mice. <i>Biochemical Pharmacology</i> , <b>2015</b> , 98, 484-92	6	5
83	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , <b>2015</b> , 129, 133-46	14.3	313
82	Treatment of anaplastic glioma. <i>Cancer Treatment and Research</i> , <b>2015</b> , 163, 89-101	3.5	17
81	Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. <i>Glia</i> , <b>2015</b> , 63, 78-90	9	39
80	Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122046	3.7	45
79	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. <i>Acta Neuropathologica</i> , <b>2015</b> , 129, 867-73	14.3	200
78	Proximity ligation assay evaluates IDH1R132H presentation in gliomas. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 593-606	15.9	27
77	Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. <i>Oncotarget</i> , <b>2015</b> , 6, 31050-68	3.3	35
76	Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 117, 85-92	4.8	10
75	A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6304-13	12.9	89
74	Challenging cytomegalovirus data in glioblastoma. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 165	1	9
73	Understanding and targeting alkylator resistance in glioblastoma. <i>Cancer Discovery</i> , <b>2014</b> , 4, 1120-2	24.4	23
72	Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. <i>Journal of Neurochemistry</i> , <b>2014</b> , 131, 251-64	6	29
71	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 561-71	14.3	148
70	Microenvironmental clues for glioma immunotherapy. <i>Current Neurology and Neuroscience Reports</i> , <b>2014</b> , 14, 440	6.6	33
69	A vaccine targeting mutant IDH1 induces antitumour immunity. <i>Nature</i> , <b>2014</b> , 512, 324-7	50.4	481
68	Aryl hydrocarbon receptor control of a disease tolerance defence pathway. <i>Nature</i> , <b>2014</b> , 511, 184-90	50.4	436

67	MGMT testing--the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , <b>2014</b> , 10, 372-85	15	316
66	Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors. <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 673	8.4	232
65	Mutant IDH1: An immunotherapeutic target in tumors. <i>OncolImmunology</i> , <b>2014</b> , 3, e974392	7.2	19
64	Trial watch: IDO inhibitors in cancer therapy. <i>OncolImmunology</i> , <b>2014</b> , 3, e957994	7.2	166
63	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 1630-8	18	59
62	Good maths is needed to understand CMV data in glioblastoma. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 2991-2	7.5	8
61	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 409-14	11.5	126
60	CMV infection and glioma, a highly controversial concept struggling in the clinical arena. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 332-3	1	23
59	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2003-2003	2.2	10
58	Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. <i>Oncotarget</i> , <b>2014</b> , 5, 1038-51	3.3	189
57	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 443-51	14.3	239
56	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 907-15	14.3	211
55	The endogenous tryptophan metabolite and NAD <sup>+</sup> precursor quinolinic acid confers resistance of gliomas to oxidative stress. <i>Cancer Research</i> , <b>2013</b> , 73, 3225-34	10.1	90
54	Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. <i>Journal of Neuroimmunology</i> , <b>2013</b> , 265, 106-16	3.5	67
53	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. <i>Neurology</i> , <b>2013</b> , 81, 1515-22	6.5	160
52	Aryl hydrocarbon receptor (AhR) regulation of inflammation and cancer. <i>Toxicology Letters</i> , <b>2013</b> , 221, S29	4.4	
51	Moderne Therapiestrategien bei hirneigenen glialen Tumoren. <i>InFo Neurologie &amp; Psychiatrie</i> , <b>2013</b> , 15, 38-51	0	1
50	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 1017-26	1	65

49	Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 1405-12	1	45
48	Functional MHC class II is upregulated in neurofibromin-deficient Schwann cells. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 1372-5	4.3	5
47	Protein kinase C $\delta$ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 14735-40	11.5	41
46	A3.18 Synovial Fibroblasts Inhibit Inflammatory T Cell Responses through Tryptophan Metabolism. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A20.1-A20	2.4	
45	Moderne Therapiestrategien bei hirneigenen glialen Tumoren. <i>Info Onkologie</i> , <b>2013</b> , 16, 32-43		
44	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2012</b> , 13, 707-15	21.7	792
43	Costimulatory protein 41gB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 105-17	12.9	91
42	Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. <i>Cancer Research</i> , <b>2012</b> , 72, 5435-40	1.4	456
41	Blood-brain barrier and brain edema. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 104, 53-62	3	6
40	The aryl hydrocarbon receptor in tumor immunity. <i>Oncoimmunology</i> , <b>2012</b> , 1, 396-397	7.2	19
39	Shaping the glioma immune microenvironment through tryptophan metabolism. <i>CNS Oncology</i> , <b>2012</b> , 1, 99-106	4	21
38	MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2000-2000	2.2	1
37	Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. <i>PLoS ONE</i> , <b>2012</b> , 7, e47663	3.7	35
36	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. <i>Nature</i> , <b>2011</b> , 478, 197-203	50.4	1185
35	Geriatric neuro-oncology: from mythology to biology. <i>Current Opinion in Neurology</i> , <b>2011</b> , 24, 599-604	7.1	20
34	Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. <i>Biochemical Pharmacology</i> , <b>2011</b> , 82, 632-41	6	28
33	Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. <i>Acta Neuropathologica</i> , <b>2011</b> , 122, 353-65	14.3	58
32	Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma. <i>BMC Cancer</i> , <b>2011</b> , 11, 127	4.8	21

31	Bevacizumab does not increase the risk of remote relapse in malignant glioma. <i>Annals of Neurology</i> , <b>2011</b> , 69, 586-92	9.4	62
30	Pathway inhibition: emerging molecular targets for treating glioblastoma. <i>Neuro-Oncology</i> , <b>2011</b> , 13, 566-79	1	104
29	The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e19823	3.7	104
28	Defective p53 antiangiogenic signaling in glioblastoma. <i>Neuro-Oncology</i> , <b>2010</b> , 12, 894-907	1	14
27	Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). <i>Stem Cells and Development</i> , <b>2010</b> , 19, 657-68	4.4	43
26	Angiotensin II sustains brain inflammation in mice via TGF-beta. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 2782-94	15.9	157
25	Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 14948-53	11.5	690
24	New (alternative) temozolomide regimens for the treatment of glioma. <i>Neuro-Oncology</i> , <b>2009</b> , 11, 69-79	1	125
23	Therapie primärer ZNS-Lymphome. <i>Onkopipeline</i> , <b>2009</b> , 2, 2-10		
22	Tumorprogress versus therapieinduzierte Veränderungen (Pseudoprogression) bei malignen Astrozytomen. <i>Onkopipeline</i> , <b>2009</b> , 2, 16-18		
21	Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. <i>Stem Cells</i> , <b>2009</b> , 27, 909-19	5.8	224
20	A novel tool to analyze MRI recurrence patterns in glioblastoma. <i>Neuro-Oncology</i> , <b>2008</b> , 10, 1019-24	1	63
19	Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. <i>PLoS Biology</i> , <b>2007</b> , 5, e257	9.7	99
18	Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3357-61	2.2	208
17	Anti-inflammatory strategies for the treatment of multiple sclerosis [tryptophan catabolites may hold the key. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2006</b> , 3, 401-408		7
16	Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. <i>Science</i> , <b>2005</b> , 310, 850-5	33.3	344
15	A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. <i>Journal of Immunology</i> , <b>2005</b> , 175, 6226-34	5.3	46
14	SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. <i>Cancer Research</i> , <b>2004</b> , 64, 7954-61	10.1	347



13	Involvement of protein kinase Cdelta and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). <i>Biochemical Pharmacology</i> , <b>2003</b> , 66, 1263-70	6	26
12	Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. <i>Annals of Neurology</i> , <b>2003</b> , 54, 388-92	9.4	180
11	MICA/NKG2D-mediated immunogene therapy of experimental gliomas. <i>Cancer Research</i> , <b>2003</b> , 63, 8996-9006	10.6	137
10	Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. <i>Microscopy Research and Technique</i> , <b>2001</b> , 52, 401-10	2.8	190
9	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta release and reduces migration and invasiveness of human malignant glioma cells. <i>International Journal of Cancer</i> , <b>2001</b> , 93, 53-61	7.5	74
8	Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. <i>Journal of Neuro-Oncology</i> , <b>2001</b> , 53, 177-85	4.8	195
7	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). <i>British Journal of Pharmacology</i> , <b>2001</b> , 134, 1279-84	8.6	18
6	Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. <i>Journal of Immunology</i> , <b>2001</b> , 166, 7238-43	5.3	87
5	Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. <i>Journal of Neuroscience</i> , <b>2001</b> , 21, 3360-8	6.6	80
4	Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. <i>Oncogene</i> , <b>2000</b> , 19, 4210-20	9.2	138
3	Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2000</b> , 59, 544-58	3.1	114
2	Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. <i>Biochemical and Biophysical Research Communications</i> , <b>2000</b> , 268, 607-11	3.4	120
1	Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion		2